Research programme: immunological cancer therapies - IDM Pharma

Drug Profile

Research programme: immunological cancer therapies - IDM Pharma

Latest Information Update: 22 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDM Pharma
  • Developer Pierre Fabre; Takeda America Holdings
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
  • 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
  • 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top